Ministry of Public Health Partners with Sandoz to Boost Biosimilar Drug Production
Thailand’s Ministry of Public Health has announced a collaboration with Sandoz to localize the production of biosimilar drugs, aiming to reduce import dependency and generate an estimated 3 billion baht in value.
The Thai Ministry of Public Health has officially entered into a partnership with Sandoz, a global leader in generic and biosimilar medicines, to establish local production capabilities for biosimilar drugs within Thailand. According to a report by Matichon Online on October 14, 2026, this strategic initiative is designed to decrease the nation's reliance on imported pharmaceutical products.
Officials estimate that this project will generate a market value of approximately 3 billion baht. By fostering domestic manufacturing, the government aims to improve the accessibility and affordability of advanced medical treatments for the Thai population.
For residents and long-term expatriates, this development is significant as it may eventually lead to a more stable supply chain for specialized medications and potentially lower costs for high-quality healthcare treatments. However, several details remain to be confirmed, including the specific timeline for the commencement of local production, the list of biosimilar drugs to be prioritized, and the regulatory framework that will oversee the quality control of these locally manufactured pharmaceuticals. As the project progresses, further announcements from the Ministry are expected to clarify how these changes will impact the availability of specific treatments in local hospitals and pharmacies.
